



RealRate

PHARMACEUTICAL 2019











PHARMACEUTICAL 2019



Xencor Inc Rank 46 of 371



The relative strengths and weaknesses of Xencor Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xencor Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Xencor Inc is the variable Research and Development, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 92%, being 423% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	315,727
Cost of Goods Sold	0
Intangible Assets	11,969
Liabilities, Current	53,853
Liabilities, Non-Current	0
Other Assets	237,223
Other Compr. Net Income	837
Other Expenses	0
Other Liabilities	1,198
Other Net Income	8,961
Property and Equipment	11,813
Research and Development	97,501
Revenues	40,603
Selling, General and Administrative Expense	22,472

Output Variable	Value in 1000 USD
Assets	576,732
Liabilities	55,051
Expenses	119,973
Stockholders Equity	521,681
Net Income	-70,409
Comprehensive Net Income	-69,990
Economic Capital Ratio	92%